Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial-Reference-Cited by-同舟云学术

Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial

Published:2018-06-01 Issue:6 Volume:25 Page:521-538
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Arai Hidenori¹,Yamashita Shizuya²³,Yokote Koutaro⁴⁵,Araki Eiichi⁶,Suganami Hideki⁷,Ishibashi Shun⁸,

Affiliation:

1. National Center for Geriatrics and Gerontology

2. Department of Community Medicine and Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine

3. Rinku General Medical Center

4. Department of Diabetes, Metabolism and Endocrinology, Chiba University Graduate School of Medicine

5. Department of Clinical Cell Biology and Medicine, Chiba University Graduate School of Medicine

6. Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University

7. Clinical Data Science Department, Kowa Company, Ltd.

8. Division of Endocrinology and Metabolism, Department of Medicine, Jichi Medical University

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry (medical),Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/25/6/25_44412/_pdf

Reference28 articles.

1. 1) Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C and Keech A: Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet, 2015; 385: 1397-1405

2. 2) Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS and Pedersen TR: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med, 2017; 376: 1713-1722

3. 3) Fruchart JC: Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol, 2017; 16: 124

4. 4) National Cholesterol Education Program (NCEP) Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 2002; 106: 3143-3421

5. 5) Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E and Fruchart JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation, 1998; 98: 2088-2093

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interplay between epigenetic mechanisms and transcription factors in atherosclerosis;Atherosclerosis;2024-08

2. Drug–drug interactions between pemafibrate and statins on pharmacokinetics in healthy male volunteers: Open‐label, randomized, 6‐sequence, 3‐period crossover studies;Clinical and Translational Science;2024-07-30

3. Lessons from PROMINENT and prospects for pemafibrate;Cardiovascular Diabetology;2024-07-29

4. Autophagy and mitophagy as potential therapeutic targets in diabetic heart condition: Harnessing the power of nanotheranostics;Asian Journal of Pharmaceutical Sciences;2024-06

5. Effects of Body Mass Index on Hypertriglyceridemia Associated with Oral Bexarotene Therapy: A Post Hoc Analysis of an Open-Label Comparative Clinical Study of Combined Bexarotene and Phototherapy Versus Bexarotene Monotherapy for Japanese Patients with Cutaneous T-Cell Lymphoma;Drugs in R&D;2024-06